Nghiem Lab & Global Partners Awarded $4 Million for New Merkel Cell Carcinoma T-Cell Therapy


Congratulations to UW Dermatology’s Nghiem Lab
The Danish-based partnership includes the University of Washington’s Division of Dermatology, DTU Health Tech
The Innovation Fund Denmark is a public grant agency which invests in the development of new knowledge and technology to create growth and employment in Denmark and around the world.
The project will explore the potential of this new cell therapy, personalized ImmPACT cell therapy, developed by Dr. Sine Hadrup
Merkel cell carcinoma is an aggressive cancer with very few treatment options. The partnership aims to assess the potential of the personalized ImmPACT cell product in patients, while developing the manufacturing platform needed for broad clinical evaluation.
"With the ImmPACT technology, we can stimulate a number of personally selected T cells from the patient's own blood, so that they are propagated and at the same time trained to better attack the cancer. Subsequently, the patient can have their own specially trained T-cells injected as treatment," explains Anne Reker Cordt, CEO of PokeAcell, who is coordinating the project.
Cell therapy holds large potential for the patients and we are honored by the support to the field and this project by Innovation Fund Denmark.
Learn more about this partnership and new therapy by visiting pokeacell.com